Anika Therapeutics | ANIK - Operating Profit


Anika Therapeutics reported $646K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Abbott USD 1.36B 775M Sep/2026
Agenus USD 15.05M 656K Mar/2026
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Halozyme Therapeutics USD -60.68M 3.04M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Integra LifeSciences USD 42.65M 1.36M Sep/2026
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 6.47B 1B Sep/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
MacroGenics USD -13.85M 19.59M Jun/2026
Merit Medical Systems USD 60.4M 16.25M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 4.72B 2.34B Sep/2026
Smith & Nephew USD 505M 65M Jun/2026
Stryker USD 1.79B 687M Jun/2026
Veracyte USD 18.02M 5.94M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026
Zimmer Biomet Holdings USD 341.5M 3.2M Sep/2026